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C), and triglyceride (TG) goal attainment, annual cardiovascular
disease (CVD)-related health care utilization and costs among
patients initiating combination statin and extended-release niacin
(NER) therapy (S + NER + S). METHODS: A retrospective
cohort study of patients initiating S + ERN between January 1,
2000 and June 30, 2006 was conducted utilizing medical, phar-
macy and laboratory result data from the HealthCore Integrated
Research Database. Patients were primary or secondary risk,
aged 18 years, had 1 lipid laboratory result 12 months prior
to index date, and 12 months pre- and post-index eligibility.
Clinical and economic outcomes were evaluated during the 12
months prior to and after initiation of S + ERN. Lipid goal
attainment was determined based on US national lipid guidelines.
CVD-related resource utilization and costs were annualized post-
index. Change in lipid goal attainment, annual resource utiliza-
tion and costs were tested using Generalized Estimating
Equations (GEE). Model covariates for lipid goal attainment
included age, gender, time to NER addition, and co-morbidity
index. RESULTS: A total of 845 (51% secondary risk) patients
initiating NER + S were identiﬁed. Patients were predominantly
male (77%), mean age 52.6 (9.05) years and time to addition
of NER was 225 (306) days. Mean change in lipid values
(mg/dL) for LDL-C, HDL-C, and TG was (-)10.81  30.67,
2.73  7.24 for HDL-C, and (-)22.67  106.79 respectively.
Multivariate analysis demonstrated increased likelihood of goal
attainment for LDL-C (OR: 1.56; p = 0.0016), HDL-C (OR:
1.58; p = 0.0004), and TG (OR: 1.39; p = 0.0078) after initiation
of NER + S therapy. GEE results demonstrated signiﬁcant
improvement from pre-index in annual CVD attributable
inpatient visits (17  49 vs 9  31 per 100 patients; p < 0.0001)
and total medical cost ($3214  10,282 vs. $2039  7117;
p < 0.0001). CONCLUSIONS: Comprehensive treatment
approach of combination NER + S therapy was associated with
improved change in lipid values, target lipid value attainment,
and reduced CVD-related inpatient visits and total medical cost.
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OBJECTIVES: To model the impact of the addition of ﬁxed-dose
niacin extended-release and simvastatin (NER/S) therapy to a
health plan formulary in terms of cardiovascular (CV) events and
corresponding attributable costs. METHODS: Two hypothetical
formularies with all major branded and generic lipid drugs were
modeled over a three year time horizon: a formulary not includ-
ing NER/S (current formulary) and a formulary which did
(revised formulary). Primary and secondary risk patients with1
sub-optimal lipid parameter were sampled from the HealthCore
Integrated Research Database between 1/1/2000 and 2/28/2005.
Package insert efﬁcacy of antihyperlipidemic medications in each
formulary was applied to the sample population. Changes in
clinical outcomes (combined lipid value attainment of low
density lipoprotein cholesterol, high density lipoprotein choles-
terol, and triglycerides, and CV events) between formularies were
evaluated relative to incremental change in pharmacy and CV
disease-related medical costs. Market penetration of NER/S was
assumed to be 1.5% and payer discounts of 17% and 50% were
applied to brand and generic wholesale acquisition costs.
RESULTS: For every 1% increase in NER/S market share there
was a corresponding 0.38% increase in the incremental rate of
combined OLV achievement and 0.06% decrease in the incre-
mental incidence of CV events between current and revised for-
mularies. Total health system drug expenditure increased by 15%
while CV event costs decreased by 10%. The incremental cost
per CV event avoided was $46,593 and $12,957 per CV event
related hospital day avoided. CONCLUSIONS: The addition of
NER/S to the health plan formulary increases combined optimal
lipid value achievement and correspondingly reduces the three
year incidence of CV events and CV event related costs in this
hypothetical patient population.
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OBJECTIVES: This analysis aims to explore management of
acute coronary syndromes (ACS) from acute event to hospital
discharge in France. METHODS: This 12-month prospective,
observational study recruited ACS patients undergoing percuta-
neous coronary intervention (PCI), January-August 2007,
capturing practice patterns, resource use and quality of life. In
France, all interventional cardiologists were invited to partici-
pate. RESULTS: 497 ACS-PCI patients (483 analyzed), enrolled
by 59 interventional cardiologists from public university
hospitals-36%, public non-university hospitals-45%, and private
hospitals-19%, were: mean age 60.9 +/- 12.8, mean weight
79.7 kg +/- 14.8, 18% female, 16% diabetics and 12% prior
myocardial infarction (MI). Index diagnosis was: unstable angina
or non-ST-elevation MI (UA/NSTEMI)-53% and ST-elevation
MI (STEMI)-47%. Almost all patients (96%) were implanted
stents: 67% bare metal stents (BMS), 23% drug eluting stents
(DES) and 11% both. Antiplatelet loading oral medications used
were aspirin-91% and clopidogrel-95% (no use of ticlopidine).
Antithrombotic agents were infused too: abciximab-16%,
tiroﬁban-18%. eptiﬁbatide-3%, and bivalirudin-3%. Clopi-
dogrel loading dose (LD) was given in intensive care unit-32%,
emergency room-24%, ambulance-21%, previous hospital-12%,
catheter lab-6% and other ward-4%, and close to PCI (previous
6 hours, during or after) in 46% of cases. Total clopidogrel
loading dose was over 300 mg in 34% of cases, and in-hospital
maintenance dose (MD) was 150 mg in 26%, and 75 mg in 74%
of cases. At time of hospital discharge, 96% of patients were
receiving clopidogrel (discharge dose 150 mg in 23%) and
EQ-5D QoL score was a median 0.85 (IQR 0.73–1.00). CON-
CLUSIONS: These data reﬂect contemporary real-life manage-
ment of ACS patients in France. DES are implanted 3 times less
than BMS. Variation in oral antiplatelet agent dosing pattern (LD
and MD) and timing of administration is frequent.
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OBJECTIVES: To collect location of care, resource utilization,
utilities and quality of life data in relation to post-stroke physical
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disability. METHODS: Randomly selected Athens Stroke Regis-
try ischaemic stroke patients, 18 years of age or older, still alive
at least 90 days post stroke and willing to attend a study visit
were administered a 30-day retrospective resource use question-
naire, the EQ-5D, the Stroke Impact Scale (SIS-16), Modiﬁed
Rankin Scale (mRS), and Barthel Index; caregivers reported
resource use and hours of informal care. Stroke history was
obtained from registry records. RESULTS: A total of 365 sub-
jects (65% male; mean age 71 years) were enrolled at a mean
time post stroke of 2.8 years (min 0.3–max 14.2 years). At the
study visit, post-stroke disability was evenly distributed (mRS:
0 = 17%; 1 = 17%; 2 = 17%; 3 = 17%; 4 = 16%; 5 = 16%);
98% (n = 357) of patients were residing at home, but 57%
(n = 205) of these needed help with ADLs. Of the 2% (n = 8)
who resided in a long-term care facility, all had severe disability
(mRS 3,4,5). Mean informal care time received by patients with
severe disability over the previous 7 days by all caregivers in the
family was 145.4 (SD = 67.6) hours; patients with mild/moderate
(mRS 0,1,2) disability received 52.6 (SD = 44.2) hours
(p < 0.001). CONCLUSIONS: Despite moderate or severe dis-
ability in a substantial proportion of this Greek cohort, most of
these post-stroke patients were cared for by their caregivers at
home. Post-stroke impairment remains an important determi-
nant of caregiver burden well beyond the acute care period,
which can translate into signiﬁcant lost productivity costs.
CARDIOVASCULAR DISORDERS—
Patient-Reported Outcomes Studies
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OBJECTIVES: In patients with acute coronary syndromes
(ACS), continued treatment with thienopyridine regimens has
been associated with fewer major adverse cardiac events. In the
TRITON-TIMI 38 trial, prasugrel was compared to clopidogrel
in ACS patients undergoing percutaneous coronary intervention
(PCI) resulting in a 19% reduction in cardiovascular death, myo-
cardial infarction, or stroke, but an increase in TIMI deﬁned
bleeding (10.9% vs 7.9%, p < 0.001). The impact of these com-
plications on medication persistence and adherence is unknown.
The objective of this study was to compare persistence and
adherence of clopidogrel and prasugrel in TRITON TIMI-38.
METHODS: TRITON TIMI-38 was a double-blind, random-
ized, controlled trial which enrolled 13,608 patients with ACS
and planned PCI. Of the 13,608 patients enrolled, 13,457
patients received at least one dose of study drug and were evalu-
ated for this study. Patients treated with prasugrel (N = 6,741) or
clopidogrel (N = 67,16) were followed for up to 15 months.
Adherence was calculated using the medication possession ratio
(MPR), the total days with medication divided by total days in
the study. Persistence was measured as the time from random-
ization to the ﬁrst gap of >14 days between exhausting the
supplied medication and ﬁlling the next prescription. Sensitivity
analyses using gaps of 7 and 30 days were performed. Clopi-
dogrel and prasugrel adherence and persistence were compared
using multivariate linear regression, controlling for demograph-
ics and illness history. Robustness of results was examined using
alternative modeling. RESULTS: A total of 17.6% of patients
prematurely discontinued study drug (prasugrel, 17.9% vs. clo-
pidogrel, 17.3%, p = 0.382). The MPR for prasugrel (0.96) and
clopidogrel (0.96) were similar (p = 0.801). Similar persistence
levels between prasugrel-treated patients and clopidogrel-treated
patients were observed using the 14-day gap (319 vs. 322 days,
p = 0.296). Sensitivity analysis using 7-day and 30-day gaps
conﬁrmed these ﬁndings. Study drug was discontinued for a
hemorrhagic adverse event (AE) in 2.5% of prasugrel patients
compared to 1.4% of clopidogrel patients (p < 0.001) and
stopped for a non-hemorrhagic AE in 4.6% v 5.0% (p = 0.372).
CONCLUSIONS: Despite an increase in TIMI deﬁned bleeding
and an increased rate of discontinuation of study drug for a
hemorrhagic event with prasugrel, similar levels of adherence
and persistence were observed for prasugrel-and clopidogrel-
treated ACS patients with PCI in TRITON TIMI-38. Further
study will be necessary to determine whether these results can be
replicated outside of the clinical trial setting.
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OBJECTIVES: This study examined persistence with amio-
darone and sotalol and the effect of stopping treatment on atrial
ﬁbrillation (AF)-related hospitalizations and cardioversions.
METHODS: A cohort of patients with a diagnosis of AF
recorded between 1999 and 2005 was assembled from the
PHARMetrics® database. The cohort included treatment-naïve
adults aged 40 years or older who established treatment with
amiodarone or sotalol (at least two consecutive prescriptions).
Discontinuation was deﬁned as a gap in availability of the index
treatment lasting at least 60 days, or one reﬁll period plus one
month, whichever was longer. Patients were followed until out-
comes of interest or end of follow-up, deﬁned as end of admin-
istrative data, change in coverage, switching to or adding another
treatment, or restarting treatment after not persisting. The
impact of persistence on hospitalizations and on cardioversions
was assessed using Cox regression models with a time-dependent
indicator for persistence adjusting for baseline covariates.
RESULTS: Over a mean follow-up of 1.26 years of 8193 patients
(65% male, mean age 67 years), persistence with amiodarone
was 44% after one year and 60% with sotalol (median times: 9.4
vs. 19 months, respectively; p < 0.001). By the third year, only
20% were still on amiodarone and 30% on sotalol. The majority
of patients (62%) did not collect any prescription after discon-
tinuation. Of those who did, patients taking sotalol were more
likely to switch to or add another treatment, while patients on
amiodarone tended to restart on the same drug. Persistence was
associated with a decreased risk of cardioversions (hazard ratio,
HR = 0.37, 95%CI: 0.25–0.56), but only borderline with hospi-
talizations (HR = 0.86, 95%CI: 0.79–1.02). CONCLUSIONS:
Persistence with amiodarone or sotalol is generally poor, and
patients who discontinue treatment are unlikely to restart at a
later time. Stopping treatment was associated with increased
risk of cardioversions and a trend of increased AF-related
hospitalizations.
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